BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37860893)

  • 21. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients.
    Sestakova Z; Kalavska K; Smolkova B; Miskovska V; Rejlekova K; Sycova-Mila Z; Palacka P; Obertova J; Holickova A; Hurbanova L; Jurkovicova D; Roska J; Goffa E; Svetlovska D; Chovanec M; Mardiak J; Mego M; Chovanec M
    Mutat Res Genet Toxicol Environ Mutagen; 2020; 854-855():503200. PubMed ID: 32660824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of care and survival outcomes for adolescent and young adult patients with testicular seminoma in the United States: A National Cancer Database analysis.
    Stokes W; Amini A; Maroni PD; Kessler ER; Stokes C; Cost CR; Greffe BS; Garrington TP; Liu AK; Cost NG
    J Pediatr Urol; 2017 Aug; 13(4):386.e1-386.e7. PubMed ID: 28153774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.
    Narayan V; Gunnarsson O; Hwang WT; Squillante CM; Nathanson KL; Stadtmauer EA; Vaughn DJ
    Clin Genitourin Cancer; 2016 Dec; 14(6):524-529. PubMed ID: 27083130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
    Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
    Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
    Ribnikar D; Stukalin I; Bedard PL; Hamilton RJ; Jewett M; Warde P; Chung P; Anson-Cartwright L; Templeton AJ; Amir E; Hansen AR; Heng DYC; Lewin J
    Curr Oncol; 2020 Dec; 28(1):107-114. PubMed ID: 33622996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
    Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
    Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Characteristics of extracranial malignant germ cell tumours in two age groups of children (0-10 and 10-18 years). Multicentre experiences].
    Drozyńska E; Połczyńska K; Popadiuk S; Niedzwiecki M; Wiśniewski J; Balcerska A; Izycka-Swieszewska E; Bilska K; Balwierz W; Chełmecka L; Chybicka A; Dudeńko I; Karolczyk G; Kowalczyk J; Krawczuk-Rybak M; Kurylak A; Leszczyńska E; Matysiak M; Młynarski W; Pobudejska A; Sobol G; Sońta-Jakimczyk D; Szajdak K; Tredowska-Skoczeń D; Szmyd K; Trelińska J; Urasiński T; Wachowiak J; Wieczorek M; Wiśniewska-Slusarz H; Woźniak S; Woźniak W; Wysocki M
    Med Wieku Rozwoj; 2011; 15(1):16-24. PubMed ID: 21786508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group.
    Fern L; Davies S; Eden T; Feltbower R; Grant R; Hawkins M; Lewis I; Loucaides E; Rowntree C; Stenning S; Whelan J;
    Br J Cancer; 2008 Dec; 99(12):1967-74. PubMed ID: 19034273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved survival in metastatic germ-cell cancer.
    Fankhauser CD; Sander S; Roth L; Beyer J; Hermanns T
    Ann Oncol; 2018 Feb; 29(2):347-351. PubMed ID: 29161363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
    Shamash J; Mee M; Sarker SJ; Wilson P; Ansell W; Greenwood M; Berney D; Alifrangis C
    BJU Int; 2020 Jun; 125(6):843-852. PubMed ID: 31688976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
    J Clin Oncol; 1997 Feb; 15(2):594-603. PubMed ID: 9053482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982-2011.
    van Leeuwen MT; Gurney H; Turner JJ; Turner SL; Pearson SA; Laaksonen MA; Harnett P; Balakrishnar B; Sabanathan D; Vajdic CM
    Cancer Epidemiol; 2016 Aug; 43():15-21. PubMed ID: 27235952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant ovarian tumours in childhood in Britain, 1962-78.
    La Vecchia C; Morris HB; Draper GJ
    Br J Cancer; 1983 Sep; 48(3):363-74. PubMed ID: 6311234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved outcomes in metastatic germ cell cancer: results from a large cohort study.
    Hentrich M; Debole J; Jurinovic V; Gerl A
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):533-538. PubMed ID: 32772232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
    Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
    J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
    Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
    Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG).
    Germà-Lluch JR; Garcia del Muro X; Maroto P; Paz-Ares L; Arranz JA; Gumà J; Alba E; Sastre J; Aparicio J; Fernández A; Barnadas A; Terrassa J; Sáenz A; Almenar D; López-Brea M; Climent MA; Sánchez MA; Lasso de la Vega R; Berenguer G; Pérez X;
    Eur Urol; 2002 Dec; 42(6):553-62; discussion 562-3. PubMed ID: 12477650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characteristics of testicular germ cell tumors in patients aged 50 years and older: A large-scale study from the Cancer Registration Committee of the Japanese Urological Association.
    Kawai T; Tanaka Y;
    Int J Urol; 2017 Feb; 24(2):124-128. PubMed ID: 27915468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.